Omnihealth Practice

Omalizumab outperforms oral immunotherapy in multi-food allergy treatment

Food allergy is a common condition that significantly impacts patients' quality of life and carries the risk of life-threatening anaphylaxis.1,2 Until recently, treatment options were largely limited to lifelong allergen avoidance.2 However, two Food and Drug Administration (FDA)-approved therapies

IMMUNOLOGY & ALLERGY

29 Apr 2025

Emerging FPIES triggers: Why egg and peanut deserve attention

Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy characterized by delayed gastrointestinal symptoms, such as vomiting, after ingesting the trigger food.1,2 While milk, soy, and grains have long been recognized as common culprits, emerging evidence suggests that

IMMUNOLOGY & ALLERGY

09 Apr 2025

Validation of dried blood spot testing for HAE family screening in the SPPOT-HAE program

Hereditary angioedema (HAE) is a rare but potentially life-threatening genetic disorder causing recurrent episodes of severe swelling of the skin and mucosa.1 It results from either a deficiency (type 1) or dysfunction (type II) of C1 esterase inhibitor (C1-INH).1,2 Diagnosis traditionally relies on

IMMUNOLOGY & ALLERGY

09 Apr 2025

Beyond breathlessness: The evolving landscape of ILD management

Interstitial lung disease (ILD) presents as a diverse group of lung disorders, where inflammation and fibrosis drive a highly variable disease course.1,2 While some patients experience mild symptoms, others progress to debilitating respiratory failure, highlighting the unpredictable nature of ILD.1,

RESPIROLOGY

20 May 2025

Dr. Syazatul Syakirin Sirol Aflah

Consultant Respiratory Physician,
Institut Perubatan Respiratori (IPR),
Kuala Lumpur, Malaysia

Reforming penicillin allergy testing: A path to better antibiotic stewardship

Penicillin antibiotics are celebrated for their extensive bactericidal activity and overall safety, making them the most commonly prescribed antibiotics worldwide.1,2 However, the mislabeling of penicillin allergies poses a significant public health issue, especially in Mainland China.3-5 Current pe

IMMUNOLOGY & ALLERGY

19 May 2025

Professor Li, Hei Philip

Clinical Assistant Professor,
Division Chief of Rheumatology & Clinical Immunology,
Department of Medicine,
The University of Hong Kong

AAN 2025

Apr 5-9, 2025 | San Diego, United State

Neurodegenerative and prion disorders heighten risk of rapid dementia progression

Patients presenting with faster-than-expected cognitive decline may have rapidly progressive dementia (RPD) or a condition that stabilizes or reverts to a more typical progression.1 Early distinction between “true” RPD and non-RPD cases is critical, as true RPDs rapidly impair cognition and function

NEUROLOGY

10 Jun 2025

SmartRehab transforms stroke recovery through AI-powered telerehabilitation

Stroke is one of the leading causes of long-term disability worldwide, and effective post-stroke rehabilitation plays a critical role in improving functional outcomes and quality of life for survivors.1 Yet, conventional in-person rehabilitation faces numerous challenges, including therapist shortag

09 Jun 2025

CROI 2025

March 9-12, 2025 | San Francisco, United States

SARC-F shows moderate accuracy in detecting sarcopenia in people aging with HIV

People living with HIV (PLWH) face an increased risk of aging-related comorbidities, including sarcopenia.¹ Sarcopenia is defined by loss of muscle mass, strength, and function, with multiple consensus definitions incorporating these components.¹ However, these diagnostic methods require specialized

INFECTIOUS DISEASE

22 Apr 2025

App-based CBT-I reduces MDD risk in youth with insomnia: Findings from CUHK and PKU study

A study from CUHK and Peking University reveals that an app-based cognitive behavioral therapy for insomnia significantly reduces the risk of major depressive disorder, highlighting the potential of digital mental health solutions.

PSYCHIATRY

10 Apr 2025

HKUMed’s revolutionary oral arsenic trioxide for APL secures FDA & EMA designation

Acute promyelocytic leukemia (APL) is a rapidly fatal disease without timely treatment.¹ A recent breakthrough from the University of Hong Kong’s LKS Faculty of Medicine (HKUMed) is changing the global treatment landscape of APL with the development of an oral formulation of arsenic trioxide (oral-ATO).^2-7 Backed by over 20 years of clinical data, oral-ATO has now received orphan drug designation (ODD) from both the United States (US) Food and Drug Administration (FDA) and European Medicines Agency (EMA).^1,8,9 Led by Dr. Singh, Gill Harinder Harry, Clinical Associate Professor at HKUMed, the team is pioneering a new era in APL treatment, bringing this life-saving innovation from Hong Kong to the global stage.^2,7

HEMATOLOGY

06 Apr 2025

FDA approves marstacimab-hncq for hemophilia prophylaxis

The United States (US) Food and Drug Administration (FDA) has approved marstacimab-hncq, an anti-tissue factor pathway inhibitor, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (HA) without factor VIII inhibitors or hemophilia B (HB) without factor IX inhibitors (neutralizing antibodies).¹ The approval was based on results from the phase 3 BASIS trial, which showed a reduction in the annualized bleeding rate (ABR) with marstacimab-hncq compared to on-demand treatment and routine prophylaxis in patients with HA or HB without inhibitors.^1,2

HEMATOLOGY

10 Feb 2025

Higher omega-3 and omega-6 fatty acids levels linked to lower cancer incidence

Polyunsaturated fatty acids (PUFAs) have been postulated to impact cancer incidence and survival, but epidemiological evidence remains inconclusive.1 In a population-based cohort study, extensive data from the United Kingdom (UK) Biobank was used to investigate the association between plasma levels

ONCOLOGY

31 Dec 2024

Real-world long-term evidence paves the way for CGRP-pathway therapies in migraine prevention

For decades, migraine prevention relied on nonspecific, off-label drugs, often lacking large-scale clinical trials to confirm their efficacy, safety, or tolerability.^1-3 This has resulted in high discontinuation rates.^2,3However, the introduction of calcitonin gene-related peptide (CGRP) pathway-targeting therapies has revolutionized migraine management.³ At a recent symposium, Dr. Sait Ashina, Director of the BIDMC Comprehensive Headache Center and Assistant Professor at Harvard Medical School in the United States (US), discussed how beyond randomized controlled trials (RCTs), the 5-year real-world evidence (RWE) data further demonstrate the utility of CGRP pathway-targeting therapies in the evolution of migraine prevention.

NEUROLOGY

21 May 2025

Dr. Sait Ashina

Assistant Professor of Neurology and Anesthesia,
Department of Neurology and Anesthesia,
Critical Care and Pain Medicine,
Harvard Medical School
Boston, United States

Every update. In your inbox.

Get access to our exclusive articles.

Empirical PPI therapy and subtype-based treatment show similar efficacy in FD

Functional dyspepsia (FD) is a common gut-brain interaction disorder that primarily affects adults and imposes a significant economic burden.¹ Treatment guidelines vary, leading to inconsistencies in management approaches.¹ A randomized, single-blinded trial was conducted to evaluate the efficacy of subtype-specific treatment vs. empirical proton pump inhibitor (PPI) therapy in adults with FD.¹ Findings suggest that both treatment approaches significantly improved the overall symptoms and health-related quality of life (HRQoL), with no clear advantage of either, over another in FD management.¹

GASTROENTEROLOGY & HEPATOLOGY

12 Jun 2025

Dr. Chuah, Kee-Huat

Associate Professor
Consultant Gastroenterologist & Hepatologist
Faculty of Medicine, University of Malaya,
Kuala Lumpur, Malaysia

Revolutionizing psoriasis treatment: Local experience with deucravacitinib in difficult-to-treat areas

Psoriasis (PsO) is a chronic inflammatory skin disease marked by persistent inflammation and abnormal differentiation of keratinocytes.1 In difficult-to-treat areas such as the scalp and palms, treatment options commonly used to treat PsO may deliver a weaker response.1 Deucravacitinib, a first-in-c

DERMATOLOGY IMMUNOLOGY & ALLERGY

23 Apr 2025

Dr. Yeung, Chi-Keung

Honorary Clinical Associate Professor,
The University of Hong Kong
Specialist in Dermatology and Venereology

Case Sharing: Early dapagliflozin stabilizes patients with acute decompensated heart failure regardless of ejection fraction

HF is a complex condition characterized by pathophysiologic heterogeneity and the presence of congestive symptoms, particularly in cases of acute decompensated heart failure (ADHF). These factors significantly increase the risk of hospitalization due to HF worsening and CV death.

CARDIOLOGY

25 Sep 2024

Dr. Fong, Yan-Hang Esmond

Specialist in Cardiology

Harnessing the potential of deucravacitinib in the treatment of psoriasis: A case series of real-world clinical applications

DERMATOLOGY

20 Nov 2024

Professor Chan, Hin-Lee Henry Honorary

Clinical Professor,
Division of Dermatology,
Department of Medicine,
he University of Hong Kong Specialist in Dermatology and Venereology

Professor April Armstrong

Professor and Chief of Dermatology,
University of California Los Angeles

Dr. Guan, Xin

Professor and Associate Chief Physician of Dermatology,
Peking University Third Hospital

Evolving insights in Asian R/M NPC care: A case sharing of tislelizumab

ONCOLOGY

03 Dec 2024

Dr. Sumou, Ingrid Karmane

Medical Oncologist,
Macau Oncology Association

Infographics

HEMATOLOGY ONCOLOGY

The Hidden Blueprint: CGAT Reveals Key Insights for Myelofibrosis Transplant

06 Apr 2025

DERMATOLOGY

Beneath The Surface Exploring Metabolic Syndrome in Chronic Spontaneous Urticaria

10 Feb 2025

OBSTETRICS & GYNECOLOGY PSYCHIATRY CARDIOLOGY

Heartfelt Connections: The Shadow of PND on Maternal CV Health

03 Dec 2024

OPHTHALMOLOGY NEPHROLOGY

Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD

21 Jun 2024

CARDIOLOGY

CKD or No CKD: Knocking down CV risks with rosuvastatin

08 Jul 2024

NEUROLOGY

Longitudinal assessment of MCI and dementia in an essential tremor cohort

08 Jul 2024

HEMATOLOGY

From bridging to maintenance: A case of gilteritinib in RR FLT3 AML patients undergoing HSCT

09 May 2024

NEUROLOGY

Real-world effectiveness of fremanezumab in migraine prevention

08 Apr 2024

HEMATOLOGY CARDIOLOGY

Incidence of anemia with long-term low-dose aspirin

18 Mar 2024

Decoding the spectrum of tolerance in fish allergies

04 Jan 2024

DIABETES & ENDOCRINOLOGY CARDIOLOGY

Earlier and higher risk of CVD with a younger T2D diagnosis

04 Jan 2024

DIABETES & ENDOCRINOLOGY

U-shaped relationship between sleep duration and T2DM regardless of traditional lifestyle risk factors

17 Nov 2023

RESPIROLOGY

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023

DIABETES & ENDOCRINOLOGY NEUROLOGY

The nuanced link between prediabetes and dementia

23 Aug 2023

NEUROLOGY RHEUMATOLOGY

Connecting the dots between Parkinson’s disease and rheumatoid arthritis

12 Jul 2023

CARDIOLOGY PEDIATRICS

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023

RESPIROLOGY IMMUNOLOGY & ALLERGY

Targeting TSLP for severe asthma - Tezepelumab updates from the 2023 American Academy of Allergy Asthma & Immunology Annual Meeting

06 Apr 2023

HEMATOLOGY PEDIATRICS

A new way out for alpha thalassemia major - Give them a chance at life with In-utero transfusions

15 Mar 2023

RESPIROLOGY

Beware of overlapping phenotypes in severe asthma: The eosinophilia and IgE double whammy

27 Feb 2023

NEPHROLOGY

Stay on the path of treatment - Take on a high-K with ease
ASN abstract highlight on sodium zirconium cyclosilicate and hyperkalemia

23 Feb 2023

RESPIROLOGY

Real-world effectiveness of benralizumab around the globe

06 Dec 2022

RESPIROLOGY

Remission is within reach - Target the underlying drivers of inflammation with benralizumab

19 Sep 2022

ONCOLOGY RESPIROLOGY

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC